212 related articles for article (PubMed ID: 37481701)
1. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates.
Powers S; Likhite S; Gadalla KK; Miranda CJ; Huffenberger AJ; Dennys C; Foust KD; Morales P; Pierson CR; Rinaldi F; Perry S; Bolon B; Wein N; Cobb S; Kaspar BK; Meyer KC
Mol Ther; 2023 Sep; 31(9):2767-2782. PubMed ID: 37481701
[TBL] [Abstract][Full Text] [Related]
2. Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome.
Matagne V; Borloz E; Ehinger Y; Saidi L; Villard L; Roux JC
Neurobiol Dis; 2021 Feb; 149():105235. PubMed ID: 33383186
[TBL] [Abstract][Full Text] [Related]
3. Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome.
Sinnett SE; Gray SJ
Discov Med; 2017 Oct; 24(132):153-159. PubMed ID: 29272692
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of a Human-Ready mini
Sadhu C; Lyons C; Oh J; Jagadeeswaran I; Gray SJ; Sinnett SE
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254921
[TBL] [Abstract][Full Text] [Related]
5. Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice.
Sinnett SE; Boyle E; Lyons C; Gray SJ
Brain; 2021 Nov; 144(10):3005-3019. PubMed ID: 33950254
[TBL] [Abstract][Full Text] [Related]
6. A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome.
Matagne V; Ehinger Y; Saidi L; Borges-Correia A; Barkats M; Bartoli M; Villard L; Roux JC
Neurobiol Dis; 2017 Mar; 99():1-11. PubMed ID: 27974239
[TBL] [Abstract][Full Text] [Related]
7. The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis.
Forlani G; Giarda E; Ala U; Di Cunto F; Salani M; Tupler R; Kilstrup-Nielsen C; Landsberger N
Hum Mol Genet; 2010 Aug; 19(16):3114-23. PubMed ID: 20504995
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome.
Collins BE; Merritt JK; Erickson KR; Neul JL
Genes Brain Behav; 2022 Jan; 21(1):e12739. PubMed ID: 33942492
[TBL] [Abstract][Full Text] [Related]
9. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice.
Gadalla KK; Bailey ME; Spike RC; Ross PD; Woodard KT; Kalburgi SN; Bachaboina L; Deng JV; West AE; Samulski RJ; Gray SJ; Cobb SR
Mol Ther; 2013 Jan; 21(1):18-30. PubMed ID: 23011033
[TBL] [Abstract][Full Text] [Related]
10. Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model.
Vermudez SAD; Gogliotti RG; Arthur B; Buch A; Morales C; Moxley Y; Rajpal H; Conn PJ; Niswender CM
Genes Brain Behav; 2022 Jan; 21(1):e12752. PubMed ID: 34002468
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome.
McCauley MD; Wang T; Mike E; Herrera J; Beavers DL; Huang TW; Ward CS; Skinner S; Percy AK; Glaze DG; Wehrens XH; Neul JL
Sci Transl Med; 2011 Dec; 3(113):113ra125. PubMed ID: 22174313
[TBL] [Abstract][Full Text] [Related]
12. MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy.
Rastegar M; Hotta A; Pasceri P; Makarem M; Cheung AY; Elliott S; Park KJ; Adachi M; Jones FS; Clarke ID; Dirks P; Ellis J
PLoS One; 2009 Aug; 4(8):e6810. PubMed ID: 19710912
[TBL] [Abstract][Full Text] [Related]
13. Ocular MECP2 protein expression in patients with and without Rett syndrome.
Jain D; Singh K; Chirumamilla S; Bibat GM; Blue ME; Naidu SR; Eberhart CG
Pediatr Neurol; 2010 Jul; 43(1):35-40. PubMed ID: 20682201
[TBL] [Abstract][Full Text] [Related]
14. A methyl-CpG-binding protein 2-enhanced green fluorescent protein reporter mouse model provides a new tool for studying the neuronal basis of Rett syndrome.
Schmid RS; Tsujimoto N; Qu Q; Lei H; Li E; Chen T; Blaustein CS
Neuroreport; 2008 Mar; 19(4):393-8. PubMed ID: 18287934
[TBL] [Abstract][Full Text] [Related]
15. MECP2 mutations in Serbian Rett syndrome patients.
Djarmati A; Dobricić V; Kecmanović M; Marsh P; Jancić-Stefanović J; Klein C; Djurić M; Romac S
Acta Neurol Scand; 2007 Dec; 116(6):413-9. PubMed ID: 17986102
[TBL] [Abstract][Full Text] [Related]
16. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with bone disease severity in Rett syndrome.
Caffarelli C; Gonnelli S; Pitinca MDT; Camarri S; Al Refaie A; Hayek J; Nuti R
BMC Med Genet; 2020 Jan; 21(1):21. PubMed ID: 32005172
[TBL] [Abstract][Full Text] [Related]
17. Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).
Bosch ME; Aldrich A; Fallet R; Odvody J; Burkovetskaya M; Schuberth K; Fitzgerald JA; Foust KD; Kielian T
J Neurosci; 2016 Sep; 36(37):9669-82. PubMed ID: 27629717
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.
Samaco RC; Hogart A; LaSalle JM
Hum Mol Genet; 2005 Feb; 14(4):483-92. PubMed ID: 15615769
[TBL] [Abstract][Full Text] [Related]
19. Exploring the possible link between MeCP2 and oxidative stress in Rett syndrome.
Filosa S; Pecorelli A; D'Esposito M; Valacchi G; Hajek J
Free Radic Biol Med; 2015 Nov; 88(Pt A):81-90. PubMed ID: 25960047
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of MECP2 mutations in New Zealand Rett syndrome patients.
Raizis AM; Saleem M; MacKay R; George PM
N Z Med J; 2009 Jun; 122(1296):21-8. PubMed ID: 19652677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
